06.15.15
Actavis has officially adopted Allergan plc as its new global name. The name change follows the acquisition of Allergan in March 2015 and the approval of the name change by Actavis shareholders on June 5. The combination of the two companies creates one of the world's top 10 pharmaceutical companies by revenue.
"Today is an exciting day for Allergan and our 30,000 employees around the world who have helped us reach this special moment," said Brent Saunders, chief executive officer and president of Allergan. "By adopting the Allergan name, we are ensuring that our corporate identity reflects the transformation of our company within the pharmaceutical industry and our position as a dynamic new breed of company – a leader in Growth Pharma. Allergan is home to world-renowned brands, the best-in-class global generics business, a premier pharmaceutical pipeline of medicines including brands, generics, biosimilars, OTC products and devices, as well as the fourth largest distributor in the U.S., which will retain the name Anda."
Allergan has initiated a rebranding campaign for the transition of its facilities, operations and commercial presence around the world. The company's U.S. and Canadian generics business will continue to operate under the Actavis name.
"Today is an exciting day for Allergan and our 30,000 employees around the world who have helped us reach this special moment," said Brent Saunders, chief executive officer and president of Allergan. "By adopting the Allergan name, we are ensuring that our corporate identity reflects the transformation of our company within the pharmaceutical industry and our position as a dynamic new breed of company – a leader in Growth Pharma. Allergan is home to world-renowned brands, the best-in-class global generics business, a premier pharmaceutical pipeline of medicines including brands, generics, biosimilars, OTC products and devices, as well as the fourth largest distributor in the U.S., which will retain the name Anda."
Allergan has initiated a rebranding campaign for the transition of its facilities, operations and commercial presence around the world. The company's U.S. and Canadian generics business will continue to operate under the Actavis name.